Tatva Chintan Pharma Chem Ltd

The provided transcript and document pages do not mention any current or planned fundraising activities through debt or equity. Key points related to funding are: - The company is undertaking a CAPEX of Rs. 70 crores for expansion, funded from internal or existing resources (no mention of external fundraising). - Earlier CAPEX of about Rs. 150-250 crores was done during the IPO, but no new equity or debt raising is indicated. - The company is confident about meeting future growth with existing capacity expansions without mentioning fresh fundraising. - No specific references to raising funds through debt or equity in the near future were made during the call or presentation. Hence, no current or future fundraising through debt or equity is disclosed in this material.

- The company announced a capital expenditure (CAPEX) of Rs. 70 crore, expected to be commercialized by October 2024. - This CAPEX is for an add-on facility at the Dahej site, including 150 KL reactors and a separate distillation plant, aiming to support commercialization of new products in the PASC (Pharma and Agro intermediates) segment. - The Rs. 70 crore investment is to capture growth opportunities and avoid delivery mismatches, expected to generate incremental revenue of Rs. 95-100 crore. - The company also received environmental clearance for a greenfield project at Jolva, Dahej, with construction planned to start in 2025. - Further CAPEX was about Rs. 250 crore from IPO proceeds, leading to asset turn improvements and capacity expansion across PTC, SDA, and PASC segments. - Additional continuous flow reactors are being added at the lab and pilot scales as part of ongoing development projects.

- PTC segment: Organic volume growth of 10-15% per year historically; 2023 may see no volume growth due to sharp product price drops; topline degrowth expected in 2023; business stable with secured large MNC customers for 2024. - PASC and SDA segments: Expected to drive future growth with commercialization starting August 2024; incremental revenue of Rs. 200 crores from PASC and Rs. 80-100 crores from SDA over next 3 years. - Overall growth guidance: At least 70% revenue growth anticipated in FY25 driven by volume growth and new products; value erosion due to lower product pricing considered in forecasts. - Capacity Utilization: Full utilization expected from July-August 2024; new CAPEX of about Rs. 70 crores underway to expand capacity. - Longer-term: Growth supported by sustained export demand (~70% of revenue from exports); SDA segment demand to benefit post-2027 with BS-7 emission norms implementation.

- FY24 guidance: revenue expected in the range of Rs. 400-410 crore with EBITDA around 20% levels. - FY25 outlook: anticipated growth of at least 70% in revenue driven by volume growth and new customer acquisitions, especially in SDA and PASC segments. - From October 2024, plant is expected to operate at full capacity leading to margin expansion; realistic margin target around 25%. - Incremental revenue over next 3 years: Rs. 200 crore from PASC (60%) and Rs. 80-100 crore from SDA (40%). - PTC segment expected to remain stable with 10-15% organic volume growth yearly, but topline degrowth in FY24 due to price erosion. - New CAPEX Rs. 70 crore planned to scale up production capacity, with full utilization anticipated from July-August 2024, boosting EBITDA. - BS-7 SDA opportunity expected to materialize in FY26, supporting long-term growth. - Overall, margin and profit growth expected post full capacity utilization and commercialization of new products.

- For the calendar year 2024, Tatva Chintan Pharma Chem Limited has already secured business with most of its existing large MNC customers in the PTC segment, indicating a stable orderbook. - Commercial orders have been received from a new potential customer after formal approvals on three different applications, with a fourth under validation, suggesting modest business in the first half and decent volumes from end of 2024. - The company is fully qualified with two additional new customers for automotive applications, expecting business onset from April quarter. - Approval progress with large customers in the electrolyte salts and PASC segments also indicates forthcoming order inflow, with commercial supplies expected to start by mid to late 2024 and 2025. - The business pipeline includes 6 new product commercializations scheduled from August 2024 onwards, which is expected to lead to capacity utilization and revenue growth.